<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01951924</url>
  </required_header>
  <id_info>
    <org_study_id>I10E-0901</org_study_id>
    <nct_id>NCT01951924</nct_id>
  </id_info>
  <brief_title>LIME Study (LFB IVIg MMN Efficacy Study)</brief_title>
  <acronym>LIME</acronym>
  <official_title>A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig® in Patients With Multifocal Motor Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratoire français de Fractionnement et de Biotechnologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and safety of I10E (LFB 10% ready-to-use
      liquid human intravenous immunoglobulin) compared to Kiovig® for the maintenance treatment of
      MMN in a randomized, double-blind, active comparator-controlled, cross-over trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multifocal motor neuropathy (MMN) is a chronic acquired, probably autoimmune, demyelinating,
      motor neuropathy. It is a rare disease, variable in its clinical features. The disease course
      is usually steadily progressive.

      Intravenous immunoglobulin (IVIg) is the standard and the first line treatment for MMN. The
      Cochrane review of four randomized placebo-controlled studies showed a significant clinical
      improvement in muscle strength from IVIg in 78% of patients with MMN versus 4% with placebo
      but a non-significant improvement in disability (39% versus 11%) (van Schaik IN, 2005).
      However, IVIg treatment does not prevent a mild gradual decline in muscle strength which is
      probably due to ongoing axonal degeneration. In addition to its efficacy, IVIg is also a safe
      treatment with a positive benefit-risk ratio in MMN.

      Muscle strength measured with the Modified Medical Research Council (MMRC 10) sum score as
      described in the study of Cats (Cats EA, 2008) including 20 movements i.e. 10 muscle groups
      of the upper and lower limbs on each side was selected as the primary endpoint. Other
      parameters of muscle strength such as measurement of grip strength by dynamometer - and
      functional disability will also be evaluated to reinforce the robustness of the study and
      substantiate the efficacy of I10E in MMN patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change between I10E and Kiovig® in the original MMRC 10 sum score described by Cats 2008</measure>
    <time_frame>at 6 months and 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change between I10E and Kiovig® in: MMRC 10 new sum score (10 slightly different muscles on both sides)</measure>
    <time_frame>at 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion</measure>
    <time_frame>from 49 to 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between I10E and Kiovig® in : Rasch built MMRC sum score (Cats 2008)</measure>
    <time_frame>at 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between I10E and Kiovig® in : INCAT: upper and lower limbs</measure>
    <time_frame>at 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between I10E and Kiovig®: Grip strength</measure>
    <time_frame>at 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between I10E and Kiovig® in: MMRC 14 sum score</measure>
    <time_frame>at 6 months and 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Motor Neuron Disease</condition>
  <arm_group>
    <arm_group_label>Group A: I10E then Kiovig®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B : Kiovig® then I10E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)</intervention_name>
    <arm_group_label>Group A: I10E then Kiovig®</arm_group_label>
    <arm_group_label>Group B : Kiovig® then I10E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)</intervention_name>
    <arm_group_label>Group A: I10E then Kiovig®</arm_group_label>
    <arm_group_label>Group B : Kiovig® then I10E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient aged 18 to 80 years.

          2. Written informed consent obtained prior to any study-related procedures.

          3. Diagnosis of definite or probable MMN according to the EFNS/PNS Guideline 2010, First
             revision made by neuromuscular disease specialists with specific electrodiagnostic
             expertise.

          4. Patients treated with a stable maintenance dose within 15% of any brand of IVIg
             (Kiovig® excluded) at 1 g/kg for 1-3 days up to 2 g/Kg for 2-5 days every 4 to 8 weeks
             (+/- 7 days), according to the EFNS/PNS Guideline 2010, First revision for at least 3
             months prior to enrolment.

          5. Covered by national health care insurance system if required by local regulations.

        Exclusion Criteria:

          1. Upper motor neuron, bulbar, cranial nerve or significant sensory deficit.

          2. CSF protein &gt;100 mg/dL (if available and done as part of a previous evaluation).

          3. Any other ongoing disease that may cause neuropathy, such as toxin exposure, dietary
             difficency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus
             erythematosus or other connective diseases, infection with HIV, hepatitis B virus
             (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström's
             macroglobulinemia, amyloid, and hereditary neuropathy.

          4. BMI &gt;= 40 kg/m2.

          5. Known hypersensitivity to the active substance or to any of the excipients of I10E
             (glycine and polysorbate 80) or Kiovig(glycine).

          6. Patient who have been treated with Kiovig shall not have received Kiovig during the
             last 6 months prior to enrolment.

          7. History of IgA deficiency, except if the absence of anti-IgA antibodies is documented.

          8. Protein-losing enteropathy characterised by serum protein levels &lt;60 g/l and serum
             albumin levels &lt;30 g/l or nephrotic syndrome characterised by proteinuria &gt;=3.5 g/24
             hours, serum protein levels &lt;60 g/l and serum albumin levels &lt;30 g/l.

          9. History of cardiac insufficiency (New York Heart Association (NYHA) III/IV),
             uncontrolled cardiac arrythmia, unstable ischemic heart disease, or uncontrolled
             hypertension.

         10. History of venous thrombo-embolic disease, myocardial infarction, or cerebrovascular
             accident.

         11. Risk factor for blood hyperviscosity such as cryoglobulinemia or haematological
             malignancy with monoclonal gammopathy.

         12. Glomerular filtration rate &lt;80 ml/min/1.73m2 measured according to the Modified Diet
             in Renal Disease (MDRD) calculation.

         13. Serum levels of AST, ALT &gt;2 times upper limit of normal range.

         14. Treatment within 12 months prior to screeening with immunomodulator or
             immunosuppressant agent (including but not limited to cyclophosphamide, cyclosporine,
             interferon-a, interferon-b 1a, anti-CD20, alemtuzumab, azathioprine, etanarcept,
             mycophenolate mofetil, methotrexate, haematopoietic stem cell transplantation).

         15. Administration of another investigational product within the last month prior to
             inclusion.

         16. Plasma exchange, blood products or derivatives administered with the last 3 months
             prior to screening.

         17. Woman with positive results of pregnancy test or breast-feeding woman or woman of
             childbearing potential without an effective contraception.

             Effective contraception are injectible, patch or combined oestro-progestative or
             progestative contraceptives, Cooper T or levonorgest releasing intra-uterine devices,
             depot intramuscular medroxyprogesterone, subcutaneous progestative contraceptive
             implants, condoms or occlusive caps (diaphragm or cervical/vault caps) with
             spermicide, true abstinence (when this is in line with the preferred and usual
             lifestyle of the patient).

         18. Any serious medical condition that would interfere with the clinical assessment of
             I10E or prevent the patient from complying with the protocol requirements.

         19. Anticipated poor compliance of patient with study procedures during the 12 month
             duration of the study.

         20. Drug or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc LEGER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de la Pitié Salpêtrière - Paris 75013</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux -Hôpital Haut-Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Créteil - Groupe Hospitalier Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon - Hôpital Pierre Wertheimer</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille - Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Paris - Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Genova - Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas</name>
      <address>
        <city>Milan</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria San Giovanni Battista</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2013</study_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multifocal Motor Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

